Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Press/Media: Press / Media

PeriodOct 2 2018

Media coverage

1

Media coverage

  • TitlePhase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
    Media name/outletClinical Trials.gov
    CountryUnited States
    Date10/2/18
    PersonsEric J Lawitz